160 related articles for article (PubMed ID: 35760475)
1. Recent updates in diagnosis and management of drug-resistant tuberculosis in India: A paradigm shift and the way ahead during the COVID-19 crisis.
Gupta M; Ish P; Malhotra N
Indian J Tuberc; 2022 Jul; 69(3):264-267. PubMed ID: 35760475
[TBL] [Abstract][Full Text] [Related]
2. One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India.
Das M; Dalal A; Laxmeshwar C; Ravi S; Mamnoon F; Meneguim AC; Paryani R; Mathur T; Singh P; Mansoor H; Kalon S; Hossain FN; Lachenal N; Coutisson S; Ferlazzo G; Isaakidis P
Clin Infect Dis; 2021 Nov; 73(9):e3496-e3504. PubMed ID: 33079176
[TBL] [Abstract][Full Text] [Related]
3. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.
Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C
Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
[TBL] [Abstract][Full Text] [Related]
5. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
[TBL] [Abstract][Full Text] [Related]
6. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
7. Strengthened capacity of India´s bedaquiline Conditional Access Programme for introducing new drugs and regimens.
Sachdeva KS; Arora N; Solanki R; Singla R; Sarin R; Bhatnagar A; Khanna A; Atahavale A; Shridhar R; Barua SR; Parmar M; Farooq SI; Ramachandran R; Alavadi U; Swamickan R; Tonsing J; Patel Y; Singla N
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1067-1072. PubMed ID: 33126941
[No Abstract] [Full Text] [Related]
8. Drug-resistant tuberculosis: advances in diagnosis and management.
Günther G; Ruswa N; Keller PM
Curr Opin Pulm Med; 2022 May; 28(3):211-217. PubMed ID: 35220372
[TBL] [Abstract][Full Text] [Related]
9. Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review.
Migliori GB; Pontali E; Sotgiu G; Centis R; D'Ambrosio L; Tiberi S; Tadolini M; Esposito S
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28178199
[TBL] [Abstract][Full Text] [Related]
10. Introduction and scaling up of new drugs for drug-resistant TB: experiences from the Americas.
Bernal O; Lopez R; Montoro E; Avedillo P; Westby K; Ghidinelli M
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1058-1062. PubMed ID: 33126939
[TBL] [Abstract][Full Text] [Related]
11. In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates.
Chandramohan Y; Padmanaban V; Bethunaickan R; Tripathy S; Swaminathan S; Ranganathan UD
J Glob Antimicrob Resist; 2019 Dec; 19():348-353. PubMed ID: 31226332
[TBL] [Abstract][Full Text] [Related]
12. Current and developing therapies for the treatment of multi drug resistant tuberculosis (MDR-TB) in India.
Muniyandi M; Ramachandran R
Expert Opin Pharmacother; 2017 Sep; 18(13):1301-1309. PubMed ID: 28786691
[TBL] [Abstract][Full Text] [Related]
13. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
[TBL] [Abstract][Full Text] [Related]
14. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
[TBL] [Abstract][Full Text] [Related]
15. Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.
Pontali E; Visca D; Centis R; D'Ambrosio L; Spanevello A; Migliori GB
Curr Opin Pulm Med; 2018 May; 24(3):244-252. PubMed ID: 29470252
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.
Soeroto AY; Lestari BW; Santoso P; Chaidir L; Andriyoko B; Alisjahbana B; van Crevel R; Hill PC
PLoS One; 2019; 14(2):e0213017. PubMed ID: 30818352
[TBL] [Abstract][Full Text] [Related]
17. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
[TBL] [Abstract][Full Text] [Related]
18. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
19. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
Barvaliya SV; Desai MK; Panchal JR; Solanki RN
Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
[TBL] [Abstract][Full Text] [Related]
20. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Seaworth BJ; Griffith DE
Microbiol Spectr; 2017 Mar; 5(2):. PubMed ID: 28361737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]